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Renal function after release of ureteral obstruction: Rote of endothelin
and the renal artery endothelium. Glomerular filtration rate (GFR) and
effective renal plasma flow (ERPF) are decreased and mean arterial
pressure (MAP) is increased after unilateral release of bilateral ureteral
obstruction (BUO). An imbalance between vasoconstnctor and vaso-
dilator substances may explain the hemodynamic alterations seen in
this setting. The present study examines the role of endothelin-l in such
alterations. Rats with BUO (N = 10) had significantly lower GFR and
ERPF (mi/mm/kg body wt) than sham-operated rats (SOR, N = 9) (1.40
0.14vs. 6.20 0.38and 5.12 0.68vs. 20.2 2.20, respectively) and
significantly higher MAP (mm Hg) than SOR (154.9 3.2 vs. 120.6
1.7). Rats with BUO given a specific antiendothelin antibody (N = 8)
had significantly higher GFR (2. 10 0.12) and ERPF (7.46 0.95) than
BUO control rats, but there were no significant changes in MAP (159.5
5.8). In SOR (N = 6), mechanical denudation of the main renal artery
endothelium did not significantly affect renal function when compared
to renal function in control SOR. However, the same maneuver
significantly lowered GFR (0.64 0.17) and ERPF (1.67 0.36) in
BUO rats (N = 5) when compared to BUO control rats. We conclude
that: (1) endothelin-l has a significant vasoconstrictor rote in rats with
BUO of 24 hours duration and accounts for a portion of the decrease in
glomerular filtration rate seen in rats after unilateral release of bilateral
ureteral obstruction, and (2) in the BUO setting, the net role of the renal
artery endothelium is vasodilatory.
A marked vasoconstriction of the renal vascular bed is the
predominant hemodynamic alteration seen after unilateral re-
lease of bilateral ureteral obstruction (BUO) of 24 hour duration
[1, 2]. This vasoconstriction is accompanied by a significant rise
in systemic mean arterial pressure (MAP) and significant de-
creases in effective renal plasma flow (ERPF) and glomerular
filtration rate (GFR). The dramatic changes in renal function
and systemic blood pressure seen after unilateral release of
BUO of 24 hours duration appears to be due to an imbalance in
the release and/or activity of vasoconstrictive and vasodilatory
substances. We have reported previously a significant patho-
physiological role for several vasoconstrictive substances dur-
ing the period of obstruction. These vasoconstrictors include
thromboxane A2 [3], angiotensin II [4], and antidiuretic hor-
mone [5]. In each of these studies [3—5], the use of specific
antagonists [5] or inhibition of the synthesis of these vasocon-
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strictors [3, 4] resulted in significant increases in ERPF and
GFR. We have also reported a vasoconstrictive role for prod-
ucts of the 5-lipooxygenase pathway of arachidonic acid metab-
olism, and in particular vasoactive leukotrienes during BUO
[6]. Inhibition of the 5-lipooxygenase resulted in significantly
greater values for GFR and ERPF in rats with unilateral release
of BUO of 24 hour duration. On the other hand, it is possible
that vasodilatory substance(s) are decreased in this setting, or
not increased to a sufficient degree to balance the increased
activity of the vasoconstrictor substances. Administration of
prostaglandins E2 and 12 117] and subpicomolar concentrations of
platelet-activating factor (PAF) following inhibition of the syn-
thesis of thromboxane A2 [8] increased GFR and ERPF signif-
icantly, but not to normal values. This suggests that other
vasodilator(s) and/or vasoconstrictor(s) also play a role in the
altered hemodynamics seen after relief of obstruction. We have
recently reported a prominent role of endothelium-derived
relaxing factor (EDRF) in obstructive nephropathy [9]. Rats
given L-arginine, the specific precursor of EDRF synthesis, had
significantly greater GFR and ERPF and lower MAP after
unilateral relief of BUO than temporal controls. These studies
suggest an important role for metabolic products of the vascular
endothelium in the altered renal hemodynamics observed in rats
with BUO.
In the present study we examined the role of the renal
vascular endothelium and of endothelin- 1, another product of
vascular endothelium, in the hemodynamic alterations seen in
rats after unilateral release of BUO of 24 hours duration. Our
results indicate that the renal artery endotheliuni and endothe-
lin, a potent vasoconstrictor, influence the changes in renal
hemodynamics observed with ureteral obstruction.
Methods
Animals
Studies were performed in female Sprague-Dawley rats ob-
tained from Sasco Inc (Omaha, Nebraska, USA) and weighing
193 to 260 g (mean 224 2 g). Rats were housed five or six to
a cage and maintained in a 12 hour light/dark cycle at 2 lC.
They had free access to water and were fed a standard rat chow
containing 22.8% protein (Ralston Purina, Saint Louis, Mis-
souri, USA). All experiments were performed a minimum of
seven days after arrival of the animals.
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Induction of bilateral ureteral obstruction (BUO) or sham-
operation
These procedures were performed in 44 rats as described
previously [8]. Twenty-three rats underwent BUO and 21
sham-operation. With animals under light ether anesthesia both
ureters were ligated at the junction of the lower one third and
the upper two thirds through a small suprapubic abdominal
incision. In sham-operated rats (SOR) both ureters were mobi-
lized but not ligated. After surgical procedures rats were
returned to their cages. Contrary to rats that had BUO, SOR
had free access to water. Both groups of rats were fasted for the
next 24 hours and the functional studies described below were
performed.
Denudation of the renal arterial endothelium
This procedure was performed in five rats with BUO and six
SOR through the same small suprapubic abdorrjinal incision
made at the time of the ureteral ligation or sham operation. The
renal arteries were exposed and rubbed with cotton applicators
for 25 to 40 seconds. No dissection of the adventitia was
necessary and extreme care was taken not to disturb surround-
ing lymphatic drainage or nerve supply. There was immediate
and adequate renal perfusion after the procedure, as assessed
by direct visual inspection. After surgical procedures the rats
were returned to their cages. Completeness of the endothelial
denudation was confirmed at the end of clearance studies in
three SOR and three rats with BUO in which the abdominal
aorta and both renal arteries were obtained, cleaned of sur-
rounding tissue, cut sagittally, fixed in 10% formalin, stained
with hematoxylin and eosin and examined under light micros-
copy. There was no endothelium in any of the renal arteries that
had been rubbed (Fig. 1). The renal artery endothelium was
intact in rats in which the arteries were not rubbed (Fig. 1).
Clearance studies and mean arterial pressure (MAP)
determinations
These procedures were performed as described previously
[8]. Briefly, 24 hours after either BUO or sham-operation the
rats were lightly anesthetized with ether, followed by the
insertion of a femoral vein catheter (PE 50), a femoral artery
catheter (PE 10) and either a left ureteral catheter (PE 50, rats
with BUO) or a bladder catheter (Tygon®, SOR). The rats were
secured in plastic holders and allowed to awaken. After two
hours, during which animals were allowed to recover from
anesthesia and surgery, a priming dose of inulin and para-
aminohippuric acid (PAH) was administered in 1 ml of normal
saline over a three-minute period, so as to achieve plasma
concentrations of these compounds of 50 to 150 mg/dl for inulin
and 1 to 2 mg/dl for PAH. Then a solution containing appropri-
ate amounts of inulin and PAH in normal saline, to maintain
plasma concentrations of these compounds constant, was given
through the femoral vein catheter at a rate of 40 .d/min. After
one hour of equilibration three 20-minute urine collections were
obtained with blood being drawn from the femoral arterial
catheter at the midpoint of each urine collection. Blood samples
were centrifuged immediately at 3000 rpm for five minutes,
hematocrit was determined and plasma separated for measure-
ments of inulin, PAH, sodium, and potassium. Mean arterial
pressure was measured continuously through a transducer
connected to the left arterial catheter (WECO, VT-i Model,
Electronic Co, Millbrae, California, USA).
Anti-endothelin antibody administration
The antibody used, which was obtained commercially (Pep-
tides International, Louisville, Kentucky, USA), was raised in
rabbits and is directed against human/porcine endothelin. This
antiserum has 100% cross-reactivity with rat endothelin. Stud-
ies by Yamada and Yoshida [10] have demonstrated that a
1:10,000 dilution of the antiserum binds approximately 50% of
the radiolabeled endothelin at a concentration of 1.3 pmol/ml.
The antibody does not cross react with other biological sub-
stances such as angiotensin I, angiotensin II, atrial natriuretic
peptide, antidiuretic hormone, secretin, /3-endorphin, calcitonin
or Peptide YY [10]. The antiserum was diluted 1:100 with
phosphate buffered solution (pH 7.40) and administered through
a miniosmotic pump (Model 1003D, Alzet Co, Palo Alto,
California, USA) delivering 1 p1/hr. The dilution factor was two
orders of magnitude less than the one shown to bind 50% of
radiolabeled endothelin [10]. The miniosmotic pump containing
100 p1 of the solution with the anti-endothelin antibody was
inserted through a small suprapubic incision 24 hours prior to
either BUO or sham-operation and the antibody was delivered
until the time of study, two days later.
To validate the in vivo efficacy of intraperitoneal administra-
tion of the antibody the experiments described below were
conducted. After baseline clearance studies performed as de-
scribed above endothelin-1 (Peptides International) was contin-
uously infused i.v. (12 ng/kg/min) into SOR or rats subjected to
unilateral release of BUO. For these studies endothelin (0.11
mg) was dissolved in acetic acid (0.46 ml) and kept at —20°C.
The day of the study an appropriate aliquot was thawed and
dissolved in the solution containing inulin and PAH that was
being infused into the rats (40 p1/mm). Administration of
endothelin to SOR (N = 3) decreased GFR by 36% (6.03 0.22
vs. 3.86 0.41 ml/min/kg body wt, P < 0.05), and ERPF by
25% (16.0 0.81 vs. 12.0 1.13 ml/min/kg body wt, P <0.03),
and increased MAP by 16% (120 5 vs. 139 6 mm Hg, P <
0.01) when compared to baseline values. In contrast, rats that
had the antiserum being delivered intraperitoneally for 24 hours
prior to sham operation (48 hr prior to clearance studies) had
only a 17% decrease in GFR compared to baseline measure-
ments (6.09 24 vs. 5.10 0.15 mllmin/kg body wt, P value not
significantly different), an 8% decrease in ERPF (14.2 0.6 vs.
12.0 0.1 mI/mm/kg body wt, P not significantly different), and
no change in MAP (142 4 vs. 142 4 mm Hg). Administration
of endothelin to rats subjected to unilateral release of BUO of
24 hours duration decreased GFR by 20% (1.60 0.14 vs. 1.28
0.14 ml/min/kg body wt, P < 0.02) and ERPF by 25% (8.03
0.69 vs. 6.06 0.34 ml/min/kg body wt, P <0.05) and increased
MAP by 5% (142 2 vs. 149 2 mm Hg, P < 0.03) when
compared to baseline measurements. In contrast, BUO rats
given the antiserum intraperitoneally for 24 hours prior to BUO
(48 hr prior to unilateral release of BUO) and then given
endothelin had only a 5% decrease in GFR (2.03 0.12 vs. 1.93
0.21 mI/mm/kg body wt, P not significantly different), a 6%
decrease in ERPF (7.48 0.31 vs. 7.02 0.14 mI/mm/kg, body
wt, P not significantly different), and a 6% increase in MAP (151
5 vs. 161 11 mm Hg, P not significantly different) when
compared to baseline values.
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Fig. 1. The renal artery endothelium was
intact in rats in which the arteries were not
rubbed (A, top). Notice the absence of
endothelium in the renal artery that was
rubbed (B, top) (refer to Methods).
Experimental group
Three groups of SOR (Groups 1 through 3) and three groups
of rats in which BUO was unilaterally released (Groups 4
through 6) were studied. Group 1 consisted of nine rats that
served as temporal control SOR. Group 2 consisted of six rats
that had denudation of the endothelium of the main renal
arteries at the time of the sham operation. Group 3 consisted of
six rats that had a miniosmotic pump inserted intraperitoneally
24 hours prior to sham operation to deliver a solution containing
a specific anti-endothelin antibody at a rate of I pd/hr. Group 4
consisted of 10 rats with BUO that served as controls. Group 5
consisted of five BUO rats that had denudation of the endothe-
hum of the main renal arteries at the time of BUO, and group 6
consisted of eight rats that received the anti-endothelin anti-
body as described above.
Analytic determinations
Inulin concentrations in plasma and urine were determined
using the anthrone method of White and Samson [III. PAH
concentrations in plasma and urine were determined according
to the method of Smith et al [121. Sodium and potassium
concentrations in plasma and urine were determined by flame
photometry.
Calculations and statistics
Clearances of inulin (C) and PAH (CI,AH) were calculated
according to a standard formula. In SOR the results are
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Table 1. Data for body weight, hematocrit, MAP and tubular function in 6 groups of rats
SOR BUO
Control
N=10 (—) EndotheliumN=5
Anti-endothelin
antibodyN=8
Control
N=9 (—) EndotheliumN=6
Anti-endothelin
antibodyN=6
Body wt g
Hematocrit %
Urine flow .d/min
MAP mm Hg
UNaV p.Eq/min
FENa* %
FEK %
FEHZO%
219 3
43.1 0.8
36.4 4.70
120.6 1.7
2.80 0.6
1.55 0.31
20.8 3.1
2.38±0.23
224 5
42.0 1.9
23.0 4.9
119.5 1.0
2.28 0.6
1.08 0.31
18.3 2.9
1.39±0.27a
224 4
46.0 0.9
42.3 14.8
129.7 21b,c
1.38 0.5
0.74 0.25
19.5 1.8
1.60±0.33
221 4
44.9 0.7
38.8 4.3
154.9 3.2
4.20 0.66
9.90 2.03
82.4 6.5
13.5±2.1
209 6
45.0 1.3
13.3 1.90"
163.8 5.1
1.11 0.24"
6.27 1.35
118 14.8"
11.7±2.3
218 5
43.6 0.3
42.5 4.70C
159.5 5.8
4.1 0.67
9.10 1.80
63.6 93C
11.1±2.1
Data are by ANOVA.
P < 0.05 for comparisons between control SOR and SOR that had renal artery endothelium removed
b p < 0.05 for comparisons between control SOR and SOR that recieved anti-endothelin antibody
P < 0.05 for comparisons between SOR that had renal artery endothelium removed and SOR that received anti-endothelin antibody
d P < 0.05 for comparisons between control BUO rats and BUO rats that had renal artery endothelium removed
P < 0.05 for comparisons between BUO rats that had renal artery endothelium removed and BUO rats that received anti-endothelin antibody
expressed per one kidney. Results are expressed as mean
standard error of the mean. Intragroup comparisons were
performed by paired t-test. Intergroup comparisons were per-
formed by means of analysis of variance (ANOVA) with
Bonferroni's correction [13]. Differences were considered sig-
nificant when P <0.05.
Results
Values for body weight, hematocrit, urine flow, MAP, total
and fractional sodium excretion, fractional excretion of potas-
sium and fractional excretion of water obtained during the
clearance studies in the three groups of SOR and the three
groups of rats with unilateral release of BUD, are summarized
in Table 1. There were no significant differences in body weight
or hematocrit among the six different groups of rats studied.
No significant changes in glomerular or tubular function were
seen in SOR in which the endothelium of the main renal arteries
had been removed (Group 2) or that had received the continu-
ous infusion of the anti-endothelin antibody (Group 3) when
compared to SOR that served as controls (Group 1). In fact, in
these rats, the values for GFR (Fig. 2), ERPF (Fig. 3), hema-
tocrit, urine flow, total and fractional sodium and fractional
potassium excretion (Table 1) were not significantly different
from those obtained in SOR that served as controls. Fractional
excretion of water was slightly lower, but statistically signifi-
cant, in SOR that had the endothelium of the main renal arteries
removed than in control SOR (Table 1). SOR given the anti-
endothelin antibody had significantly higher MAP values (P <
0.002) than the other two groups of SOR. Rats with unilateral
release of BUD that served as controls (Group 4) had signifi-
cantly lower values for GFR (1.40 0.14 vs. 6.20 0.38
ml/min/kg body wt, P < 0.0001, Fig. 2) and ERPF (5.12 0.68
vs. 20.2 2.20 mllmin/kg body wt, P < 0.0001, Fig. 3) than
those obtained for one kidney in control SOR (Group 1). Rats
with BUO that had the endothelium of the main renal arteries
mechanically removed (Group 5) had significantly lower values
for GFR (0.64 0.17 ml/min/kg body wt, P < 0.003, Fig. 2) and
ERPF (1.67 0.36 mL/min/kg body wt, P < 0.01, Fig. 3) than
control BUO rats. Rats with BUO that received anti-endothelin
antibody intraperitonealy during the 48 hours prior to clearance
0
BUO
Fig. 2. Values for glomerular filtration rate (GFR) in sham-operated
rats (SOR) and in rats in which bilateral ureteral obstruction (BUO) has
been unilaterally released. Mechanical denudation of the endothelium
of the renal artery (-Endothelium) or administration of a specific
anti-endothelin antibody (Anti-Eti Ab) did not affect GFR significantly
in SOR when compared to temporal control rats (•). Mechanical
denudation of the endothelium of the renal artery () significantly
decreased GFR in BUD rats when compared to BUD rats that served as
temporal controls. Administration of an anti-endothelin antibody (Ill)
significantly increased GFR in BUD rats when compared to BUD rats
that served as temporal controls. *D < 0.05 when compared to temporal
control BUO rats.
studies (Group 6) had significantly higher values for GFR (2.10
0.12 mi/mm/kg body wt, P < 0.002, Fig. 2) and ERPF (7.46
0.95 mi/mm/kg body wt, P < 0 .04, Fig. 3) than BUO rats that
P
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SOR BUO
Fig. 3. Values for effective renal plasma flow (ERPF) in sham-oper-
ated rats (SOR) and in rats in which bilateral ureteral obstruction
(BUO) has been unilaterally released. ERPF was not significantly
different among the three groups of SOR. In BUO rats denudation of the
renal artery endothelium () significantly decreased ERPF and admin-
istration of an anti-endothelin antibody (tZ significantly increased
ERPF when compared to those values in BUO rats that served as
temporal controls (U). *p < 0.05 when compared to temporal control
BUO rats.
served as controls (Group 4). The blockade of endothelin with
the specific antibody in BUO rats increased the levels of GFR
and ERPF to values that were 34% for GFR and 36% for ERPF
of the values obtained in one kidney in SOR treated with
antibody. Values for urine flow, MAP, total and fractional
sodium excretion, fractional potassium excretion, and frac-
tional water excretion were not significantly different in anti-
body-treated BUD rats than in BUD control rats (Table 1).
MAP was significantly greater in rats with BUO than in SOR
(Fig. 4). There was a significant increase in MAP in SOR given
the anti-endothelin antibody (Fig. 4).
Rats with BUO that had the endothelium of the main renal
arteries removed (Group 5) had significantly lower values for
urine flow, total sodium excretion and fractional potassium
excretion than BUO rats that served as controls (Table 1).
Discussion
The results of this study indicate that endothelin [14, 151 has
an important role in the renal functional alterations seen after
unilateral release of BUD of 24 hours duration. As previously
demonstrated in this and other laboratories, rats in which BUD
was unilaterally released (Group 4) had a severe reduction in
GFR and a marked increase in systemic arterial pressure when
compared to values obtained for one kidney in control SOR
(Group 1). In BUO control rats GFR was about 23% (P <
0.00001) and ERPF about 25% (P <0.00001) of the respective
values obtained in SOR. MAP was approximately 35 mm Hg
higher (P < 0.00001) in BUO control rats than in control SOR.
In addition, BUO control rats had significant alterations in
tubular function as demonstrated by greater values for frac-
tional sodium excretion, fractional potassium excretion and
fractional water excretion, when compared to values obtained
in control SOR.
Rats with BUD given a specific anti-endothelin antibody
(Group 6) had values for GFR and ERPF that were significantly
greater than those obtained in BUO control rats (Group 4). GFR
and ERPF values in antibody-treated BUO rats were 34% and
36%, respectively, of the values obtained in one kidney of
control SOR, thus suggesting that other vasodilators and/or
vasoconstrictors play a role in this setting [2—9]. The mecha-
nisms underlying the significant increase in GFR and ERPF in
BUO rats given the anti-endothelin antibody cannot be defini-
tively established from the present experiments. It is possible
that the endothelin antibody resulted in a significant decrease in
the biological activity of this potent vasoconstrictor in vivo.
Alternatively, it may be possible that in the setting of endothelin
inhibition, the biological activity of other vasodilator sub-
stances predominates to shift the balance toward vasodilata-
tion. In this respect, the unopposed effect of EDRF as a
vasodilator in the absence of an effect of endothelin during its
30
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Fig. 4. Values for mean arterial blood pressure (MAP) in three groups
of sham-operated rats (SOR) and three groups of rats in which bilateral
ureteral obstruction (BUO) has been unilaterally released: (U) rats that
served as temporal controls; () rats with renal arteries denuded of
endothelium; (tLl) rats given anti-endothelin antibodies. Rats with BUO
had significantly higher values for MAP than SOR. There were no
significant differences in MAP values among the three groups of BUD
rats. SOR given the anti-endothelin antibody had significantly higher
levels of MAP (* < 0.05) than the other two groups of SOR.
]
SOR BUO
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blockade by a specific antibody may explain the higher value for
GFR and ERPF in rats with BUO of Group 6. In contrast,
administration of the anti-endothelin antibody to SOR (Group 3)
did not produce significant changes in GFR or ERPF when
compared to untreated SOR (Group 1), and if anything, those
values were lower than, though not statistically different from,
control SOR of group 1.
We did not have a ready explanation for the significant
increase in MAP seen in SOR given the anti-endothelin anti-
body. Inasmuch as in vitro cross-reactivity of this antibody with
other biological substances has not been reported, it is still
possible that an unidentified interaction could have taken place
in vivo, such that it resulted in a significant increase in MAP in
these rats. Although the exact nature of such an interaction is
unknown to us, we speculate that the antibody may demon-
strate intrinsic endothelin activity through stimulation of endo-
thelin receptors. In another study [16] there were no variations
in MAP or renal function after intravenous bolus infusion of
anti-endothelin antibody, which argues against the possibility of
intrinsic stimulation of endothelin receptors by the antibody.
However, there are differences between our study and that of
Kon et a! [16]: first, the antiserum was infused constantly
through an ip route instead of being given as a bolus, and
second, we performed studies on animals in the awake state
after at least 48 hours of continuous delivery of the antiserum.
At any rate, whether or not there was intrinsic stimulation of
endothelin receptors in the present studies, it is possible that
MAP was significantly higher in SOR given the antibody as a
result of secondary stimulation of the activity of other vasocon-
strictors or decreased activity of other vasodilators. Since we
did not know the pharmacokinetics of the antiserum during its
slow intraperitoneal infusion we cannot rule out other possible
biologic interactions following the absorption and metabolism
of the antibodies. Whatever the reason for the hypertensive
effect of this antibody, we do not have data to either prove or
disprove the above-mentioned postulates.
Since a number of the vasomodulators are either synthesized
or metabolized in the vascular endothelium we explored the
overall role of the vascular endothelium of the main renal
arteries in the setting of obstruction. We denuded mechanically
the endothelium of the main renal arteries by external rubbing
of short duration at the time of either sham operation or BUO.
That this method resulted in complete denudation of the endo-
thelium in these vessels was confirmed by histological exami-
nation of the arteries obtained at the completion of the clear-
ance studies. In SOR denudation of the endothelium of the main
renal arteries did not result in significant changes in renal
function or MAP. This observation is not in agreement with that
previously reported by Kon et al [17]. Those investigators
showed a marginal but statistically significant decrease in GFR
(of about 10%) in anesthetized Munich-Wistar male rats in
which the left main renal artery had been subjected to mechan-
ical de-endothelization when compared to the GFR obtained in
the contralateral untouched side. In those experiments there
were no significant differences in ERPF in the de-endothelized
kidney when compared to the untouched kidney. Despite the
differences in strain and gender, which may or may not be
important, there are some other differences that may explain
the results obtained in our study and that of Kon et al. First, we
performed de-endothelization of both main renal arteries; sec-
ond, we performed clearance studies at least 24 hours after
de-endothelization; third, we studied our animals in the awake
state, that is, at least four hours had elapsed after surgery and
anesthesia; and fourth, we used another group as a control.
Thus, it is possible that, as shown by Kon et a!, the immediate
effect (observed within minutes of the surgical procedure) of the
removal of the endothelium from the main renal artery is a
slight, but statistically significant, decrease in GFR but not in
ERPF. However, that effect is functionally overcome in SOR
after 24 hours of de-endothelization. In contrast, in rats with
BUO that had denudation of the endothelium of the main renal
arteries the lack of the endothelium resulted in a further
decrease in renal function. This suggests that in the setting of
BUO the endothelium of the main renal arteries produces
and/or releases predominantly more vasodilatory than vasocon-
strictive substances, or produces and/or activates significantly
less vasoconstrictive than vasodilatory substances. Indeed, we
have demonstrated that administration of L-arginine, the sub-
strate for the synthesis of endothelium-derived relaxing factor
(EDRF), to BUO rats results in greater values for ERPF and
GFR and lower values for MAP [9]. Denudation of the endo-
thelium of the main renal arteries may decrease the production
of EDRF. Our results suggest that the balance between vaso-
dilator and vasoconstrictive substances is not altered after the
endothelium of the main renal arteries is removed in SOR.
The overall role of endothelin in the altered hemodynamics
seen in rats studied after unilateral release of BUO of 24 hour
duration appears to be modest when compared to the increased
activity of other vasoconstrictors or the decreased activity of
other vasodilators known to play a significant role in this
setting. Table 2 summarizes the relative importance of the
different manipulations of the systems known to modulate renal
function in BUO rats. As shown in Table 2, increased activity of
vasoconstrictive substances appears to play a more significant
role than decreased activity of the vasodilators studied. In
particular, inhibition of the angiotensin converting enzyme, and
hence the renin-angiotensin system axis, resulted in an increase
in GFR to about 76% of the normal values obtained for one
kidney in SOR, and this effect was potentiated to 90% by
simultaneous inhibition of the synthesis of thromboxane A2. As
shown in Table 2, the role of endothelin in the altered hemo-
dynamics seen in BUO rats is modest when compared to the
renin angiotensin system or the 5-lipooxygenase pathway of the
arachidonic acid, and at least similar in magnitude to the role of
thromboxane A2 alone or the antidiuretic hormone.
L-arginine, PAF, and atrial natriuretic peptide (ANP) are
among the vasodilators that play a role in the alterations seen in
rats subjected to unilateral release of BUO of 24 hours duration.
Administration of L-arginine, the substrate for EDRF synthe-
sis, increased GFR to about 50% of the values obtained per one
kidney in SOR. Administration of platelet-activating factor in
the setting of prior inhibition of TxA2 synthesis increased GFR
to about 60% of values seen for one kidney in a normal rat. ANP
administration increased GFR after unilateral release of BUO to
about 40% of values seen for one kidney in SOR.
Most of these studies have examined the contribution of one
or at most two vasoactive substances on the changes in ERPF
and GFR that occur with ureteral obstruction. The interactions
among all the vasoconstrictive and vasodilatory substances
known to play a role in the hemodynamic changes that occur in
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Table 2. Overall role of vasoconstrictors and vasodilators in the
renal hemodynamic alterations seen after bilateral ureteral
obstruction
GFR in rats after unilateral
release of bilateral ureteral
obstruction compared to GFR
in one kidney of sham-operated
rats %
Before After
Maneuver used [Reference] maneuver maneuver
Inhibition of synthesis or
activity of
vasoconstrictors
RAS inhibition 20.7 75.8
RAS and TxA2 inhibition [4] 23.5 90.5
Prevention of macrophage 21,5 52.3
infiltration [6]
TxA2 synthesis inhibition [6] 17.0 29.7
LT synthesis inhibition [6] 21.5 49.5
Inhibition of ADH V1 22.3 35.8
receptors [5]
Endothelin antibody 21.0 33.8
[present study]
De-endothelialization of the 21.0 10.2
main renal arteries
[present study]
Administration or activation of
vasodilators
L-arginine administration 24.3 49.2
(for EDRF synthesis) [9]
TxA2 inhibition and PAF 17.0 57.6
administration [8]
ANP administration [18] 24.8 39.5
Induction of the cytochrome 17.0 40.0
p450 system (unpublished
observations)
Results are summarized from [4—6, 8, 9 and 18]. Abbreviations are:
GFR, glomerular filtration rate; SOR, sham-operated rats; RAS, renin-
angiotensin system; TxA2, thromboxane A2; LT, leukotrienes; ADH,
antidiuretic hormone; EDRF, endothelium-derived relaxing factor;
PAF, platelet-activating factor; ANP, atrial natriuretic peptide.
the kidney in vivo following release of ureteral obstruction have
not been examined in detail.
In summary, prior inhibition of the biological action of
endothelin- 1 by using a specific antibody significantly increased
GFR and ERPF in rats subjected to unilateral release of BUO of
24 hours duration. This protective effect is not mediated by
changes in systemic blood pressure. In addition, the overall role
of the renal artery endothelium appears to be predominantly
one of vasodilation. We conclude that endothelin-1 and the
renal artery endothelium play a modest but significant role in
the hemodynamic alterations seen in rats with unilateral release
of BUO of 24 hour duration. Endothelin-l accounts for about
14% of the decrease in GFR and ERPF in this setting, and the
lack of endothelium lessens renal function even more, from 21%
(baseline in BUO rats) to only 10% of the values seen per one
kidney in control SOR.
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